On April 8, 2022 BrickBio, the leader in RNA facilitated site-specific conjugation for novel protein therapeutics, reported that it will be presenting an invited poster at the annual meeting of the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Conference on April 11th, 2022 during the Antibody-Drug Conjugates Session (Press release, BrickBio, APR 8, 2022, View Source [SID1234611780]). BrickBio will be located at Booth #3334 throughout the conference.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BrickBio has commercialized its’ novel protein conjugation platform which leverages engineered RNA to introduce site-specific chemistries into any protein while maintaining a homogenous product for best-in-class therapeutics with improved safety, efficacy and dosage. The conjugation platform enables the conjugation of multiple distinct payloads on a single protein and the conjugation of two or more molecules to generate novel therapeutics.
The pipeline candidate depicted in the poster (#3940), Next Generation Site-Specific ADCs targeting Breast and Gastric Cancer was developed using the previously revealed Site-Select Panel and highlights the advantage of the powerful ADC platform towards breast & gastric cancer with improved efficacy, better safety, and overall lower dosage. Identification of the optimal sites are currently being transferred between next-generation antibody scaffolds, such as bispecifics, nanobodies, or other fragments in BrickBio’s undisclosed pipeline.
BrickBio’s pioneering, undisclosed efforts towards Protein Origami Therapeutics and Synthetic Virology are also highlighted, which leverage the same core technology that drive Brick’s novel ADCs. Protein Origami enables the spatial orientation of multiple proteins into a multimeric complex, resulting in synergistic modalities that have yet to be explored due to the inability to generate such structures prior to BrickBio. In addition, Synthetic Virology advancements revolve around the retargeting of capsids via protein conjugation to engineer tropisms, improve safety, increase infectivity, and eliminate immunogenicity. BrickBio is rapidly expanding on its strong base of AAV modification capabilities.
BrickBio is continuing their partnership efforts throughout AACR (Free AACR Whitepaper) 2022 by meeting with potential collaborators for work on novel ADCs, Protein Origami Therapeutics, and Synthetic Virology.
"The BrickBio platform and processes have unleashed the full potential of the unnatural amino acid technology, enabling new therapeutic modalities, all linked by the same conjugation chemistries", said James Italia, VP of Commercial Development at BrickBio, "Specifically, the novel ADC platform highlights the unprecedented precision in our discovery engine, allowing us to pursue novel pipeline candidates which were previously unattainable", Italia concluded.
"BrickBio’s unique and robust platform capabilities have positioned the company to expand its’ internal pipeline of novel, best-in-class ADC candidates, co-develop novel therapeutics with partners, and develop next generation therapeutics," stated Audrey Warner, Head of Business Development of BrickBio, as well as Vice President of Investments of Tiger Gene Ventures. "BrickBio will work with top partners to develop and progress promising candidates through the clinic to ultimately reach more patients," Warner concluded.